U.S. stock market midday update: Analyst ratings did not include recommendations, Reviva Pharmaceuticals' stock price rose 10.25% against the trend, attracting attention

U.S. Stock Market Midday Update Reviva Pharmaceuticals rose 10.25%. Based on recent news, On December 24, MarketBeat reported that analysts rated Reviva Pharmaceuticals as a moderate buy, but it was not included in the recommended list. Although analysts hold a moderate buy rating for the company, they believe that five other stocks are more attractive, which may lead to increased investor interest in Reviva and drive up its stock price. On December 24, trading volume increased, indicating heightened market attention on the stock. An increase in trading volume typically suggests rising investor interest in the stock, possibly due to optimistic expectations about its future performance. No other significant news recently. The U.S. stock market has seen increased volatility lately, and risks should be monitored. Stocks with High Trading Volume in the Industry Eli Lilly fell 0.31%, with increased trading volume. Based on recent news, On December 24, Eli Lilly's innovative drug tirzepatide was officially included in the new national medical insurance catalog, leading to a new round of price reductions in the domestic diabetes and weight loss drug market, affecting Eli Lilly's market expectations. On December 25, Novo Nordisk launched a patient-facing platform, NovoCare, and significantly reduced prices, attempting to squeeze the survival space of generic drugs through a price war, which puts pressure on Eli Lilly's market share. On December 26, Eli Lilly announced it would pay $40 million for licensing, research, and collaboration, and make a $15 million equity investment to collaborate with ABL Bio on joint research based on a bispecific antibody platform, with mixed market reactions. The weight loss drug market is highly competitive, and policy impacts are significant. Novo Nordisk fell 1.37%. Based on recent news, On December 24, the Centers for Medicare & Medicaid Services announced that GLP-1 drugs would be covered under Medicaid and Medicare, which is expected to put pressure on Novo Nordisk's global sales growth. On December 24, Novo Nordisk's oral weight loss drug was approved for market launch. Although the stock price rose in the short term, it still accumulated a decline of 38.35% for the year. On December 25, the National Medical Products Administration approved Novo Nordisk's long-acting growth hormone injection, Nozivo, for market launch. Despite this positive news, it failed to reverse the overall downward trend. The GLP-1 drug market is highly competitive, with intensified price wars. Pfizer fell 0.35%, with increased trading volume. Based on recent key news: On December 23, Pfizer announced that a patient participating in a long-term study of a hemophilia drug died due to severe side effects, causing the stock price to drop by more than 1%. This incident raised market concerns about drug safety, although the company stated it would not affect patient safety. Source: Zhitong Finance On December 24, Pfizer received a tax demand worth 12.7 million rupees, which may impact the company's financial condition. Source: Zhitong Finance On December 24, analyst ratings showed a hold rating for Pfizer, which was not included in the recommended buy list, affecting market confidence. Source: MarketBeat The demand for gene therapy is weak, and the industry faces challenges. Stocks ranked among the top in industry market capitalization Johnson & Johnson fell 0.32%, with increased trading volume. Based on recent key news: On December 25, Johnson & Johnson announced that its innovative drug RYBREVANT® was approved by China's NMPA for the treatment of patients with advanced non-small cell lung cancer with EGFR mutations. This approval provides significant support for the company's expansion in the Chinese market and may drive the stock price up. On December 22, a jury in Maryland, USA, ruled that Johnson & Johnson must pay $1.56 billion in damages due to claims that its baby powder contained asbestos and caused cancer. This ruling may negatively impact the company's reputation and financial condition, putting pressure on the stock price. On December 26, Johnson & Johnson announced that the interim analysis results met the pre-set criteria for early termination of the study, indicating progress in research and development, which may have a positive impact on the stock price. The innovation in the healthcare industry is accelerating, while regulatory risks are increasing